Novo says CagriSema beat Zepbound in Phase III weight-loss trial

The wire

1. 01Novo Nordisk reported Phase III results showing its cagrilintide-semaglutide combination CagriSema outperformed Eli Lilly's Zepbound (tirzepatide) on weight loss.
2. 02A head-to-head win against tirzepatide would reset prescribing conversations and payer tiering for clinicians and operators placing patients on incretin therapy.
3. 03Full trial data, tolerability and discontinuation rates, and regulatory timing still need to be seen before the comparison can be judged.

From the source

Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study